Dedication to the highest standards of values for our clients
Rapid Validation
Obtain crucial early-stage data to rapidly validate drug efficacy and safety, accelerating decision-making and shortening development cycles.
Accelerated Global Development
Optimized procedures and expert regulatory assistance to expedite international regulatory approvals.
Access to Chinese Clinical Experts and Hospital Resources
Utilize our extensive network of Chinese clinical experts and hospital resources to ensure smooth clinical trials and high-quality data collection, facilitating successful entry into the Chinese market.
R&D and Production
Chengdu CMC Research Center
The facility covers approximately 3,000 square meters and is dedicated to the automation process and quality analysis research of radiopharmaceuticals with long, medium, and short half-lives. It aims to break down barriers in all stages of radiopharmaceutical R&D and provide high-quality, efficient R&D transformation services for domestic and international radiopharmaceutical companies.
The facility offers comprehensive and integrated imaging reading and independent evaluation services, including project preparation, document uploading, quality control (QC), data review, image evaluation, medical review, and data export.
Covers an area of over 20,000 square meters, locating only on block away from the Sichuan 177Lu Reactor Serving diagnostics for southwest China and therapeutics for Asia & Australia
Covering an area of over 10,000 square meters, the facility is transitioning into a Grade A R&D and production center. It serves the Pearl River Delta and the Guangdong-Hong Kong-Macao Greater Bay Area, with long half-life products covering major cities across China.
As a leading CRO/CDMO platform, we take pride in our extensive experience in radiopharmaceutical projects. With >20 successful projects under our belt, our expertise spans across a wide range of ligand types, from small molecules and peptides to antibodies. Our comprehensive services cover everything from early PCC validation to process development, preclinical research, clinical research, and even market authorization applications and commercial production.
We have a wealth of experience in radionuclide labeling projects, including but not limited to 177Lu, 225Ac, 68Ga, 64Cu, 18F, 89Zr, and 212Pb. In particular, we have completed >500 labeling experiments on >100 different ligands using only 177Lu-labeled products.
We have a deep understanding of the regulatory and policies in China, with successful applications of >10 clinical trials. We have established a robust supply chain and logistics management system that spans the entire upstream and downstream process, enabling us to supply high-quality radiopharmaceuticals to over 30 hospitals across China in a timely manner.
Our track record speaks volumes about our commitment to excellence and our ability to deliver results. We are not just a contract service company; we are your trusted partner in the journey towards China market.
